Taysha Gene Therapies Inc (NAS:TSHA)
$ 2.085 -0.065 (-3.02%) Market Cap: 419.88 Mil Enterprise Value: 369.69 Mil PE Ratio: 0 PB Ratio: 7.19 GF Score: 31/100

Taysha Gene Therapies Inc Corporate Update Call Transcript

Jan 31, 2023 / 09:30PM GMT
Release Date Price: $1.64 (+6.49%)
Operator

Welcome to the Taysha Gene Therapeutics -- Therapies GAN Program Update and 2023 Corporate Outlook Conference Call. (Operator Instructions). As a reminder, this webcast is being recorded today, January 31, 2023.

I will now turn the call over to Dr. Kimberly Lee, Chief Corporate Affairs Officer. Please go ahead.

Kimberly Lee
Taysha Gene Therapies, Inc. - Chief Corporate Affairs Officer

Thank you, Sherry. Good afternoon, and welcome to Taysha's GAN Program Update and 2023 Corporate Outlook Conference Call.

Earlier today, Taysha issued a press release providing an update on the TSHA-120 program in giant axonal neuropathy or GAN, and corporate outlook for 2023. A copy of this press release is available on the company's website and through our SEC filings. On this call, we will review the regulatory feedback from FDA on our giant axonal's neuropathy program, discuss next steps for it and provide a corporate overview for 2023.

Joining me on today's call are Sean Nolan, Taysha's CEO; and Sukumar Nagendran, President and Head of R&D.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot